After working with a patient in 1999 whose blood pressure was critically unstable as plasma seeped out of her blood vessels, frustrated University of Toledo doctors Joseph Shapiro and Ragheb Assaly sought out a treatment. They teamed up with UT biochemist J. David Dignam and found a solution in their plasma volume expander, Pegylated albumin -- or PEG-Alb as it is known as in the biotech biz. Toledo-based ADS Biotechnology was born. Today, with the help of UT, the northwest Ohio-based Rocket Ventures, the U.S. government and the Ohio Third Frontier Program, the firm is arranging clinical trials, hoping to go to market in the next three to five years. Besides every day uses, the treatment could be a crucial advancement for military medicine on the front lines.